Genzyme to build R&D center in Beijing

Sep. 22, 2009 (China Knowledge) - Genzyme Corp, a U.S.-based biotechnology company, over the weekend held a ground-breaking ceremony for a research and development center in Zhongguancun Life Science Park, Beijing, sources reported.

The new 200,000-square foot R&D and manufacturing complex, which is expected to be operational in 2011, will cost US$100 million and employ 350 researchers.

The Beijing R&D center will include a production laboratory for cell therapy and will enable work on several key projects in the fields of transplantation, immunology, cancer and cardiovascular diseases.

Henri Termeer, president and CEO of Genzyme, said the firm is committed to long-term development in the Chinese market.

Genzyme is looking for potential acquisition opportunities and will provide its diversified technology platform and knowledge in China. Through existing ties with local enterprises the firm will contribute to the development of disease treatment and diagnosis across the country, said Termeer.

The firm plans to develop around 20 medical products for the Chinese market in the next ten years. It currently offers only three.

Genzyme's new facility in Beijing will be its second-largest R&D base outside the U.S.